Your browser doesn't support javascript.
Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host.
Caccuri, Francesca; Messali, Serena; Bortolotti, Daria; Di Silvestre, Dario; De Palma, Antonella; Cattaneo, Chiara; Bertelli, Anna; Zani, Alberto; Milanesi, Maria; Giovanetti, Marta; Campisi, Giovanni; Gentili, Valentina; Bugatti, Antonella; Filippini, Federica; Scaltriti, Erika; Pongolini, Stefano; Tucci, Alessandra; Fiorentini, Simona; d'Ursi, Pasqualina; Ciccozzi, Massimo; Mauri, Pierluigi; Rizzo, Roberta; Caruso, Arnaldo.
  • Caccuri F; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Messali S; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Bortolotti D; Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara 44121, Italy.
  • Di Silvestre D; Proteomic and Metabolomic Laboratory, Institute of Biomedical Technologies, National Research Council (ITB-CNR), Via Fratelli Cervi, 201, Segrate 20054, Italy.
  • De Palma A; Proteomic and Metabolomic Laboratory, Institute of Biomedical Technologies, National Research Council (ITB-CNR), Via Fratelli Cervi, 201, Segrate 20054, Italy.
  • Cattaneo C; Department of Hematology, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Bertelli A; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Zani A; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Milanesi M; Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, V.le Europa, 11, Brescia 25123, Italy.
  • Giovanetti M; Laboratório de Flavivírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
  • Campisi G; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Gentili V; Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara 44121, Italy.
  • Bugatti A; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Filippini F; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Scaltriti E; Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Str. dei Mercati, 13a, Parma 43126, Italy.
  • Pongolini S; Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Str. dei Mercati, 13a, Parma 43126, Italy.
  • Tucci A; Department of Hematology, ASST Spedali Civili di Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • Fiorentini S; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
  • d'Ursi P; Institute of Technologies in Biomedicine, National Research Council, Via Fratelli Cervi, 201, Segrate 20054, Italy.
  • Ciccozzi M; Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Via Álvaro del Portillo, 21, Rome 00128, Italy.
  • Mauri P; Proteomic and Metabolomic Laboratory, Institute of Biomedical Technologies, National Research Council (ITB-CNR), Via Fratelli Cervi, 201, Segrate 20054, Italy.
  • Rizzo R; Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara 44121, Italy.
  • Caruso A; Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, P.le Spedali Civili, 1, Brescia 25123, Italy.
Virus Evol ; 8(1): veac042, 2022.
Article in English | MEDLINE | ID: covidwho-1915852
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) emerge for their capability to better adapt to the human host aimed and enhance human-to-human transmission. Mutations in spike largely contributed to adaptation. Viral persistence is a prerequisite for intra-host virus evolution, and this likely occurred in immunocompromised patients who allow intra-host long-term viral replication. The underlying mechanism leading to the emergence of variants during viral persistence in the immunocompromised host is still unknown. Here, we show the existence of an ensemble of minor mutants in the early biological samples obtained from an immunocompromised patient and their dynamic interplay with the master mutant during a persistent and productive long-term infection. In particular, after 222 days of active viral replication, the original master mutant, named MB610, was replaced by a minor quasispecies (MB61222) expressing two critical mutations in spike, namely Q493K and N501T. Isolation of the two viruses allowed us to show that MB61222 entry into target cells occurred mainly by the fusion at the plasma membrane (PM), whereas endocytosis characterized the entry mechanism used by MB610. Interestingly, coinfection of two human cell lines of different origin with the SARS-CoV-2 isolates highlighted the early and dramatic predominance of MB61222 over MB610 replication. This finding may be explained by a faster replicative activity of MB61222 as compared to MB610 as well as by the capability of MB61222 to induce peculiar viral RNA-sensing mechanisms leading to an increased production of interferons (IFNs) and, in particular, of IFN-induced transmembrane protein 1 (IFITM1) and IFITM2. Indeed, it has been recently shown that IFITM2 is able to restrict SARS-CoV-2 entry occurring by endocytosis. In this regard, MB61222 may escape the antiviral activity of IFITMs by using the PM fusion pathway for entry into the target cell, whereas MB610 cannot escape this host antiviral response during MB61222 coinfection, since it has endocytosis as the main pathway of entry. Altogether, our data support the evidence of quasispecies fighting for host dominance by taking benefit from the cell machinery to restrict the productive infection of competitors in the viral ensemble. This finding may explain, at least in part, the extraordinary rapid worldwide turnover of VOCs that use the PM fusion pathway to enter into target cells over the original pandemic strain.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Journal: Virus Evol Year: 2022 Document Type: Article Affiliation country: Ve

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Journal: Virus Evol Year: 2022 Document Type: Article Affiliation country: Ve